Sarah Cannon Research Institute | Strategic Alliance Partners

April 05, 2022

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

February 22, 2022

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

February 15, 2022

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances.

February 11, 2022

Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.

February 09, 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

January 09, 2022

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

January 08, 2022

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

December 29, 2021

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.

December 23, 2021

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

October 29, 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

October 28, 2021

Melissa Johnson, MD, discusses highlights from the 2021 ESMO Congress.

October 25, 2021

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

October 15, 2021

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

October 13, 2021

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

October 12, 2021

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

October 11, 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

October 08, 2021

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

October 05, 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

October 04, 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

October 04, 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.